Varenicline (Champix): Supply issue
Pfizer have paused distribution of all brands of varenicline.
19 January 2022
Pfizer expect to start supplying varenicline again in the second half of 2023.
The out of stock affects all presentations and brands of varenicline. Pfizer have paused distribution due to impurity concerns with their manufacturing.
Pfizer are investigating the exact cause of the issue.
What you can do
People who take varenicline
If you have any varenicline, Pfizer have advised that any product currently in the market is safe.
Please do not prescribe varenicline until it is back in stock. We are still working with Pfizer on a resupply date.
People will not be able to fill any repeats that they have. You will need to direct people back to their prescribers to discuss treatment options.
There are other funded products to support people to stop smoking. There are no current supply issues with these products.
In April 2021, Pfizer advised there would be a shortage of the Varenicline Pfizer brand. To cover the out of stock, Pharmac previously listed Pfizer's Champix brand.
Following that Pfizer notified us of a supply interruption to both brands of varenicline. Pfizer have told us that this is a global issue.
If you have questions about this out of stock, contact Pfizer
- 0800 736 363
If you have questions about the Special Authority, contact firstname.lastname@example.org